anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Risk Summary   
Available data from case reports, case series, observational studies and clinical experience with indigotindisulfonate sodium injection use in pregnant women over several decades have not identified a drug associated risk of adverse maternal and fetal adverse effects. Indigotindisulfonate sodium injection use during the first trimester of pregnancy is rare; thus, the data are insufficient to evaluate for a drug associated risk of major birth defects and miscarriage. The majority of the published data were from intra-amniotic injections. Animal reproduction studies using the intravenous route of administration have not been conducted. Oral administration of indigotindisulfonate sodium to pregnant rats and rabbits produced no evidence of fetal harm.  
However, oral availability is low (3%) so that the risk of intravenous administration of indigotindisulfonate sodium during pregnancy cannot be evaluated from the data available .  
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
PROBLEM TO BE SOLVED: To obtain a preparation for external use for skin high in safety, further improved in skin whitening effect, and capable of further improving dull skin, containing a combination of at least one kind of substance selected from L-ascorbic acid derivatives and other six kinds of compounds with an escinol (salt). SOLUTION: This skin preparation for external use contains a combination of at least one kind of substance selected from L-ascorbic acid derivatives, placenta extract, kojic acid and derivatives therefrom, azelaic acid and derivatives therefrom, glucosamine and derivatives therefrom, hydroquinone glycosides and derivatives therefrom and licorice extracts with an escinol (salt) of the formula (R<1> is H or OH; R<2> is a pyranose residue).The contents of the above two kinds of ingredients in the whole amount of the preparation are pref. 0.001-20wt.%, respectively (esp. 0.1-7wt.% for the latter). The L-ascorbic acid derivative is pref. an L-ascorbic phosphoric ester, while the hydroquinone flycoside is pref. as the hydroquinone-α-D-glucose.
Patients eligible for enrollment will receive 7-day lead-in therapy of orelabrutinib 150 mg once daily, followed by 3 cycles of orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (oFCG) at 28-day intervals. After 3 cycles, bone marrow (BM) minimal residual disease (MRD) detection and efficacy evaluation (iwCLL2018 guidelines) are conducted. If BM MRD is negative (\<10-4), patients will receive be treated with orelabrutinib plus obinutuzumab in 4-6 cycles; If BM MRD is positive (≥10-4), patients will receive the same regimen in 4-6 cycles as in previous 3 cycles. After 6 cycles of treatment, BM MRD detection and efficacy assessment will be conducted again. If BM MRD is negative (\<10-4), orelabrutinib monotherapy will be administered in 7-12 cycles; If BM MRD is positive (≥10-4), treatment with orelabrutinib plus obinutuzumab will be administered in 7-12 cycles. After 12 cycles of treatment, BM MRD detection and efficacy evaluation will be performed. If BM MRD is negative (\<10-4), orelabrutinib will be withdrawn and participants will turn to follow-up (efficacy assessment and MRD test will be performed according to the follow-up plan); if BM MRD is positive, treatment with orelabrutinib monotherapy will be administered in 13-24 cycles (continued even if BM MRD test was negative). After 24 cycles, if BM MRD is negative, the drug can be stopped and participants turn to follow-up. If BM MRD is positive, treatment can be continued until disease progression or be ceased by investigator due to no benefit from continued treatment, and BM MRD can be tested as planned. The trial is expected to end 36 months after enrollment of the last patient. If the subjects continue to require subsequent treatment with orelabrutinib, the sponsor will coordinate with the manufacturer and continue to provide the monotherapy treatment.
Tuberculosis (TB) remains one of the most important infectious diseases worldwide. According to the World Health Organization (WHO) estimates, there were 9 million new TB cases and 1.5 million related deaths in 2013. Future control strategies include early treatment for preventing transmission and treatment of latent TB infection (LTBI) for reducing reactivation. Patients with renal failure undergoing dialysis have increased risk of TB due to attenuated cellular immunity. For instance, their risk of developing active TB in the dialysis population is 7.8-25 times higher than that of the general population. However, TB diagnosis is usually delayed because of frequent extra-pulmonary manifestations. Thus, LTBI detection in this specific group is important.

Positive results of interferon-gamma release assays (IGRAs) and the exclusion of active TB are the current diagnostic bases of LTBI, which is a precursor of tuberculosis reactivation. However, recent reports show a high negative reversion rate of quantiFERON Gold In-tube (QFT-GIT), a kind of IGRA, in cohorts of health care workers (33% after 18 weeks) close TB contacts (35% after six months), and patients receiving long-term dialysis (46% after six months). This phenomenon questions the clinical significance of a single positive IGRA result. Increasing the IGRA threshold or doing serial follow-up to improve specificity have both been suggested but there is no comparison by the risk of TB development.

Therefore, increasing the accuracy and stability and then improving the rate of negative conversion from positive IGRA results are very important. Currently, new generation of QuantiFERON-TB Gold Plus includes two tubes for CD4 and CD8 T cells response, which can indicate TB immune response more specifically. The investigators applied this project to compare the performance of diagnosing LTBI by QuantiFERON-TB Gold Plus in comparing QuantiFERON-TB Gold In-tube.
<P>PROBLEM TO BE SOLVED: To obtain a polymerization initiator composition that exhibits neither burn nor ignitability even in contact with paper or the like in air, provides a polymerizable composition with polymerization activity and cures the polymerizable composition in a short time and an adhesive composition comprising the same.  <P>SOLUTION: The polymerization initiator composition for a polymerizable monomer constituting a dental adhesive composition comprises 100 parts wt. of at least one kind of an organoboron compound (A) selected from the group consisting of a trialkylboron, an alkoxyalkylboron, a dialkylborane and a partially oxidized trialkylboron, 5-40 parts wt. of an aprotic solvent (B) having 50°C-120°C boiling point and 0.2-5 parts wt. of an alcohol (C) having 60°C-180°C boiling point.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A wound dressing or other wound contact medium containing an acetyl donor compound, being free form peroxide compounds. The acetyl donor may be encapsulated within polymeric particles, and the particles may be produced by thermally induced phase separation process (TIPS). The dressing may comprise a dressing matrix to which the particles are attached. The acetyl donor may be e.g. tetraactylethylenediamine (TAED), pentaacetyl glucose (PAG), acetyl salicylic acid (ASA), amongst others, and may be a mixture. Also provided is a kit of the wound dressing and a plasma generating device configured to generate a plasma producing hydrogen peroxide, capable of activating the acetyl donor compound, to produce peracetic acid in situ. The plasma may be cold plasma. Also provided is the use of the wound dressing for us in the prevention and/or treatment of a wound infection in a patient, as well as an associated process, wherein the patient is a human or an animal. The wound dressing may be subject to the plasma producing hydrogen peroxide before and/or after it is applied to the wound.
BACKGROUND: Sarcopenia is a complication that occurs after liver transplantation (LT), and it is a poor prognostic factor.
METHODS: A total of 23 healthy controls and 131 LT patients (18 - 76 weeks of age) were enrolled in the study. Pa-tients were grouped according to the North American Working Group on Sarcopenia in Liver Transplantation by performing pre- and post-transplant CT scans of the third lumbar (L3). The serum C-reactive protein (CRP) was analyzed and the liver frailty index (LFI) was assessed. Their associations with postoperative sarcopenia, skeletal muscle index (SMI), and poor outcomes were examined.
RESULTS: Before LT, the serum CRP was increased in patients with LT, compared with the healthy subjects, and had the highest levels in patients with sarcopenia. There were seventy-nine patients with sarcopenia after LT, including 48 who had been diagnosed with sarcopenia preoperatively and 31 who had a new onset of sarcopenia after LT. There was a moderate-strength negative correlation between the preoperative and postoperative rates of change in CRP and L3 SMI. Patients assessed as frail preoperatively (LFI ≥ 4.5) were associated with postoperative sarcopenia, and 19 of the new postoperative sarcopenia cases occurred in patients assessed as frail preoperatively. The serum CRP levels and LFI were significantly higher in patients who experienced a prolonged hospitalization and early infections postoperatively than in patients without significant adverse events. CRP (post-LT) > 2.575 pg/mL (OR = 1.16, 95% CI: 1.06 - 2.39, p = 0.026) as well as frailty (OR = 1.36, 95% CI: 1.20 - 2.60, p = 0.001) were independent predictors of sarcopenia after LT in patients.
CONCLUSIONS: Serum CRP levels and LFI may be effective for an early detection of sarcopenia in patients with LT.
Verapamil hydrochloride injection is contraindicated in:

1\. Severe hypotension or cardiogenic shock.

2\. Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker).

3\. Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker).

4\. Severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy).

5\. Patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). Intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and AV conduction.

6\. Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff- Parkinson-White, Lown-Ganong-Levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. Therefore, the use of verapamil in these patients is contraindicated.

7\. Ventricular tachycardia: Administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (QRS ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. Proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting.

8\. Known hypersensitivity to verapamil hydrochloride.
ABSTRACTObjetives: Omega-3 (n3) fatty acids have been studied as an option to alleviate the harmful effects of obesity. However, its role in obesity-related behavioral changes is still controversial. This study aimed to evaluate the effects of n3 on behavior and neuroinflammation in obese animals. Methods: Male Wistar rats were divided into four groups: control diet (CT), CT+n3, cafeteria diet (CAF), and CAF+n3. Diet was administered for 13 weeks, and n3 was supplemented during the last 5 weeks. Metabolic and biochemical parameters were evaluated, as well as anxiety-like behaviors. Immunoblots were conducted in the animals' cerebral cortex and hippocampus to assess changes in neuroinflammatory markers.Results: CAF-fed animals showed higher weight gain, visceral adiposity, fasting glucose, total cholesterol, triglycerides, and insulin levels, and n3 improved the lipid profile and restored insulin sensitivity. CAF-fed rats showed anxiety-like behaviors in the open field and light-dark box tasks but not in the contextual aversive conditioning. Omega-3 did not exert any effect on these behaviors. Regarding neuroinflammation, diet and supplementation acted in a region-specific manner. In the hippocampus, CAF reduced claudin-5 expression with no effect of n3, indicating a brain-blood barrier disruption following CAF. Furthermore, in the hippocampus, the glial fibrillary acidic protein (GFAP) and toll-like receptor 4 (TLR-4) were reduced in treated obese animals. However, n3 could not reverse the TLR-4 expression increase in the cerebral cortex.Discussion: Although n3 may protect against some neuroinflammatory manifestations in the hippocampus, it does not seem sufficient to reverse the increase in anxiolytic manifestations caused by CAF.
KNX100 matching placebo will be provided in capsule form for oral administration. The placebo will be encapsulated in HPMC dark green opaque size 0 capsules and packaged in 100 mL HDPE bottles with PP twist-off closures.
FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention relates to preparing interferon- -containing compositions that are able to retain their biological activity and can be used as drugs for intranasal using, for example, for nasal drops making. Antiviral agent that is nasal drops has alpha-, beta- or gamma-interferon prepared by methods of genetic engineering with viscosity value (1.1-30.0) x 10 Pa x s, biologically compatible polymer, antioxidant, ridostin and buffer mixture. Ridostin content in the claimed agent is 0.00001-100.0 mg/1 ml of buffer mixture. Agent provides good absorption, optimal viscosity and distribution on surface of mucosa tissue with prolonged retention. EFFECT: enhanced effectiveness of antiviral agent. 3 ex
Patients who were previously diagnosed of obstructive sleep apnea (OSA) with apnea hypopnea index (AHI) \> 10 events/hr and have previously failed or refused PAP therapy. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
The placebo comparator will be Avaxim, by Sanofi Pasteur. This control vaccine was chosen because hepatitis A immunization provides a similar health prevention incentive as HPV vaccination to study participants while preserving the scientific cogency of a "placebo" comparator. Gardasil 9 requires administration of 3 doses, while Avaxim only requires 2 doses. For this reason, a placebo injection (saline solution) will be added in between the Avaxim vaccination regimen. Consequently, both treatment and control vaccines will have similar regimens, i.e., study entry, 2 months, and 6 months.
Physical fitness is one of the leading concepts of health and well-being at all stages of life. In certain context, individuals tend to engage in prolonged sedentary behaviors, and these contexts are considered sedentary-promoting environments. These environments also detrimental on physical fitness and health. University students and office workers who predominantly engage in sedentary behaviors, such as prolonged sitting and computer-based work, have consistently shown associations with various aspects of diminished physical fitness. The online intervention protocols might be a good alternative for increasing fitness level for those who live or work in highly sedentary settings. Hence, the purpose of this study is to investigate the effectiveness of 8-week online delivered exercise program on actual and perceived physical fitness components. Specifically, body composition measured by DXA, upper body muscular strength, and flexibility are the main focus of this study. Moreover, physical self-perception is also a focus of this study.
Diabetes and periodontitis are two global epidemics. There is a two-way relationship between diabetes and periodontitis. Diabetes increases the risk of periodontitis and periodontitis increases the risk for deteriorating glucose levels, having undetected diabetes, and for future diabetes. A recent Cochrane report summarized that there is moderate-certainty evidence that periodontal treatment improves glycaemic control in people with both periodontitis and diabetes. The recent PAROKRANK study found that undetected dysglycaemia was independently associated to both myocardial infarction and to periodontitis. To increase awareness of oral health in people with diabetes this article summarizes recent evidence.
A coating composition containing a crosslinkable coating composition. The coating system comprises: ingredient A that has at least two protons that can be activated to form a Michael carbanion donor; ingredient B that functions as a Michael acceptor having at least two ethylenically unsaturated functionalities each activated by an electron-withdrawing group; and a catalyst system. In one embodiment, the catalyst system comprises diethyl carbonate, quaternary ammonium hydroxide or quaternary ammonium alkoxide, ethanol and 4-6 wt. % water. In another embodiment, the catalyst system comprises carbon dioxide, quaternary ammonium hydroxide or quaternary ammonium alkoxide, ethanol and 2-4 wt. % water. In certain embodiments, the coating composition optionally further comprising ammonium carbamate (H 2 NR 8 R 9 +—OC═ONR 8 R 9 ), wherein R 8  R 9  are each independently selected from hydrogen, a linear or branched substituted or unsubstituted alkyl group having 1 to 22 carbon atoms; 1 to 8 carbon atoms; 1 to 3 carbon atoms.
A prospective controlled, unblinded clinical trial will be conducted among AKI patients who are detected by the use of AKI sniffer. The investigators will randomize consecutive patients who were detected to have AKI by AKI sniffer into two groups. In one group (control group), patients will receive standard clinical care by the primary ICU physicians. The primary physicians who take care of the control subjects will be kept blinded of the results of the AKI sniffer. All the ICU physicians will receive a copy of KDIGO (March 2012) guidelines for management of AKI prior to the initiation of the patient accrual. In the intervention group, the research team will inform the primary care team about the occurrence of the AKI and provides a copy of KDIGO guidelines for management of AKI to the clinicians. Each subject will be followed until hospital discharge or for a maximum of 3 months, for clinical and laboratory data including peak serum creatinine, creatinine at the end of follow up, peak AKIN stage, along with other secondary outcomes. The investigators will exclude the prevalent cases (AKI patients who have had AKI documented in their medical records by clinicians prior to the ICU admission).
The invention discloses a preparation method of a cholesterol derivative-based organic-inorganic composite nano vesicle. The preparation method is characterized in that: the structure of an organic-inorganic composite cholesterol derivative is Si-L-Ch, wherein the Si is a silicane head group; the L is an aliphatic chain linking group; carbon number in the L is between 2 and 18; and the Ch is a cholesterol group or a cholesterol derivative group. The method comprises the following steps of: performing derivation on a hydroxy group of a cholesterol molecule to form a carboxyl; reacting the carboxyl and an amino of garma-aminopropyltriethoxysilane (APTES) under the condition of dehydration by using EDC as a dehydrating agent; and synthesizing the novel silicane head group-containing cholesterol derivative through covalent connection of an amido bond or by directly reacting the carboxyl on the cholesterol molecule and isocyanatopropyltriethoxysilane (IPTES). The cholesterol derivative-based organic-inorganic composite nano vesicle has excellent biocompatibility. The organic-inorganic composite cholesterol derivative can perform self assembly to form a highly dispersed system similar to a liposome and is applied to embedding, transferring and sustained release of various medicaments, such as hydrophilic medicaments, oleophylic medicaments, amphiphilic medicaments and the like. The method has a simple operation process and high repeatability, can be relatively widely applied to the synthesis of a plurality of organic-inorganic composite cholesterol derivatives and has a wide application prospect.
The invention relates to a recombined pseudorabies virus of expressing pig influenza virus hemagglutinin gene and application. The pseudorabies virus and pig influenza virus can make  pregnant sows abort, and always mixed infect on clinical application. The live vaccine vector is researched by using pseudorabies virus of gE gene dificiency as carrier to prevent two diseases by one stitch. The live vector vaccine of pseudorabies virus for expressing H3 hypotype pig influenza virus HA gene is constructed by using pseudorabies virus of gE gene dificiency as carrier. The exogenous virogene inserts and replaces AccI segment of 376bp in TK gene and the exogenous virogene is expressed at the control of CMV early promoter. The recombined virus can grow in the chicken-embryo fibroblast and prepare vaccine (live vaccine) for preventing pig pseudorabies and pig influenza.
PURPOSE: Provided is a method of preparing a liquid composition containing phosphatidylserine which maintains a liquid phase even stored for a long period of time and is used as a food by preventing the viscosity of phosphatidylserine from being increased and preventing the phosphatidylserine from being hardened when dissolved in fat containing unsaturated fatty acid. Therefore, the liquid composition is used for health foods and medicines in the form of a soft gelatin capsule. CONSTITUTION: A liquid composition contains phosphatidylserine and fat that is derived from a plant, an animal or a microorganism and contains 20 to 95% by weight of medium-chain fat. The medium chain fat comprises C6-10 fatty acid. The phosphatidylserine is in the form of powders, granules or pastes, or present as a constituent. The liquid composition is prepared by blending plant, animal or microorganism-derived fat with medium-chain fat; adding phosphatidylserine to the mixture; and adding one or more solvents selected from the group consisting of hexane, ethanol and acetone and then blending the mixture at 40 to 60deg.C.
An exercise program based on the current evidence will be provided through a tablet application (ReHand) along with the face-to-face conventional approach of each recruitment centres. A follow-up of the use of the application will be carried out. The treatment protocol will last 4 weeks, including daily exercise sessions of 30-60 minutes of duration at home though the application tablet.
A method of making Cu-Ag 3 PO 4  nanoparticles is provided. The method includes forming a mixture of at least one silver salt, at least one phosphate salt, and at least one copper (II) salt. The method further includes dissolving the mixture in water. The method further includes sonicating the mixture. The method further includes precipitating the Cu-Ag 3 PO 4  nanoparticles or “nanoparticles”. The copper is present in the nanoparticles in an amount of 2 to 23 weight percent (wt.%) based on the total weight of the Cu-Ag 3 PO 4 . The nanoparticles of the present disclosure find application in treating cervical cancer, and colorectal cancer. The nanoparticles may also be used in photodegrading environmental pollutants.
Participants in this group will be asked to continue peanut in their diet for 1 year at a dose determined from the double blind placebo controlled food challenge at baseline. After the 1 year period, participants will be given another double blind placebo controlled food challenge which will be used to determine their current peanut threshold. The current peanut threshold will be used to determine which participants will go into clinical care and which will get sustained unresponsiveness food challenges to peanut.